Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Rostock International Parkinson's Disease Study (ROPAD) (ROPAD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03866603
Recruitment Status : Active, not recruiting
First Posted : March 7, 2019
Last Update Posted : March 1, 2021
Sponsor:
Information provided by (Responsible Party):
Centogene AG Rostock

Brief Summary:
Rostock International Parkinson's Disease Study - An International, multicentre, epidemiological observational study aiming at identification of 1,500 LRRK2-positive patients, the identification of 1,500 non-LRRK2 PD patients and the establishment of a candidate biomarker in the LRRK2-positive cohort.

Condition or disease
Parkinson´s Disease

Show Show detailed description

Layout table for study information
Study Type : Observational
Estimated Enrollment : 10000 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Rostock International Parkinson's Disease Study: an International, Multicenter, Epidemiological Observational Study
Actual Study Start Date : May 30, 2019
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine


Group/Cohort
Parkinson´s disease individuals
The participants that are clinically diagnosed with Parkinson's disease
Family member of a participant with LRRK2 parkinsonism
The first and second degree family members of the ROPAD Study participants with LRRK2 parkinsonism
High risk population
Populations at high risk such as Ashkenazi Jewish and Arab Berber



Primary Outcome Measures :
  1. To identify 1,500 LRRK2-positive participants [ Time Frame: 2 years ]
    The participants fulfilling the eligibility criteria will be enrolled into the Study and genetically tested for LRRK2 hotspot mutations and the whole GBA gene will be sequenced.


Secondary Outcome Measures :
  1. To identify 1,500 non-LRRK2 PD participants [ Time Frame: 2 years ]
    Participants with negative results for LRRK2 hotspots and GBA, clinically diagnosed for PD and are willing to participate in further genetic screening, 68 PD associated genes will be sequenced.


Other Outcome Measures:
  1. Establishment of candidate LRRK2-positive biomarkers in the LRRK2-positive cohort [ Time Frame: 2 years ]
    LRRK2-positive samples will be validated for the identification of potential biomarkers (based on MS/MS-Spectroscopy) and compared with a merged control sample in order to establish a LRRK2 specific biomarker.


Biospecimen Retention:   Samples With DNA
Blood sample applied on the Dry Blood Spot (DBS) Filtercard (Centocard®)


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Parkinson's disease patients and LRRK2 carriers and high risk population
Criteria

Inclusion Criteria:

  • Informed consent is obtained from the participant.
  • The participant is equal to or older than 18 years old.
  • The participant is clinically diagnosed with Parkinson's disease
  • The participant is a family member of a participant with LRRK2 parkinsonism.
  • The participant is a member of a high risk population.

Exclusion Criteria:

  • Inability to provide informed consent.
  • The participant is younger than 18 years old.
  • The participant is not suffering from Parkinson's disease.
  • The participant is not a family member of a participant with LRRK2 parkinsonism.
  • The participant is not a member of a high risk population.
  • Previously enrolled in the study.
  • Participant in custody.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03866603


Locations
Show Show 103 study locations
Sponsors and Collaborators
Centogene AG Rostock
Investigators
Layout table for investigator information
Principal Investigator: Arndt Rolfs, Prof. Dr. CENTOGENE GmbH
Publications of Results:
Layout table for additonal information
Responsible Party: Centogene AG Rostock
ClinicalTrials.gov Identifier: NCT03866603    
Other Study ID Numbers: ROPAD 01-2019
First Posted: March 7, 2019    Key Record Dates
Last Update Posted: March 1, 2021
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: The plan will be defined at a later stages

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Centogene AG Rostock:
Parkinson´s disease
Biomarker
LRRK2
GBA
PD Genetics
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases